Limb Loss
Methodology & AI Transparency ⓘ
Limb Loss Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: People can lose all or part of an arm or leg for many reasons.
- 2 Real-world patient consensus: Diagnostic registry E11.3: Limb Loss is managed within Diabetes & Glucose.
- 3 Typical cash cost range: Workup highlights for Limb Loss (E11.3): peripheral monofilament testing [Limb Loss E11.3].
- 4 Top reported side effects / signs: Key Diabetes & Glucose biomarkers for Limb Loss (E11.3): Fasting Plasma Glucose [Limb Loss E11.3] & Fasting Insulin [Limb Loss E11.3] (3.0 – 7.0 uIU/mL (E11.3)).
Ask our AI Specialists anything about Limb Loss
What Is Limb Loss?
People can lose all or part of an arm or leg for many reasons. Common ones include: Problems with the flow of blood through your body. These may be the result of atherosclerosis or diabetes. Severe cases may result in amputation (the surgical removal of a limb). Injuries, including from traffic accidents and military combat. Cancer. Birth defects. Some amputees have phantom pain, which is the feeling of pain in the missing limb. Other physical problems include surgical complications and skin problems if you wear an artificial limb . Many amputees use an artificial limb. Learning how to use it takes time. Physical therapy can help you adapt.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Limb Loss (E11.3, Diabetes & Glucose) reflects renal SGLT2 glucose in Limb Loss (E11.3: hyper-reabsorption). Cross-referenced with NIH MeSH (Amputees), longitudinal control is benchmarked via Fasting Plasma Glucose [Limb Loss E11.3].
Common Symptoms & Clinical Signs
- • Injuries, including from traffic accidents and military combat
- • Presentation of Limb Loss (E11.3): elevated fasting blood in Limb Loss (E11.3: glucose or post-meal)
- • Secondary Limb Loss clinical sign: increased thirst [Limb Loss E11.3]
- • Symptom flares in Limb Loss correlating with Fasting Plasma Glucose [Limb Loss E11.3] deviation outside 75 – 95 mg/dL (E11.3)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Limb Loss Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E11.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Plasma Glucose [Limb Loss E11.3] | 75 – 95 mg/dL (E11.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Insulin [Limb Loss E11.3] | 3.0 – 7.0 uIU/mL (E11.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Limb Loss (E11.3: mg/dL)) | > 85% (E11.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Limb Loss
Treatment selection for Limb Loss depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Limb Loss)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Liraglutide combined with metformin treatment for obese people with type 2: What a 1,289-Participant Study Found This review will offer insights for future research and provide reference for LMT treatment for ODP. Irish journal of medical science • 2023-12-15 • Meta-Analysis | N = 1,289 | 94/100 | PMID 37036569 ↗ |
| New Insights on GLP-1-based therapies and limb outcomes in: What a 240,000-Participant Study Found In real-world PAD populations, GLP-1-based therapies are associated with meaningful reductions in both limb and heart and blood vessel outcomes. Diabetes research and clinical practice • 2026-06-15 • Meta-Analysis | N = 240,000 | 94/100 | PMID 42009258 ↗ |
| New Insights on Benefits and safety of onabotulinumtoxinA with standardized physiotherapy for the: What a 381-Participant Study Found OnabotulinumtoxinA was well tolerated and effective in reducing lower limb spasticity and improving functional outcomes versus placebo in children. NeuroRehabilitation • 2022-01-15 • Phase III Randomized Trial | N = 381 | 93/100 | PMID 34957954 ↗ |
| New Insights on IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in children Cerebral: What a 350-Participant Study Found Data provide evidence for sustained real-world benefits and safety of multipattern incobotulinumtoxinA treatment in children and adolescents with upper-limb spasticity. Pediatric neurology • 2021-10-15 • Phase III Randomized Trial | N = 350 | 93/100 | PMID 34339951 ↗ |
Limb Loss Patient Community & “People Like Me” Threads
Filter Limb Loss community threads and patient logs by age, biological sex, dosage, and treatment duration.